Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor

2015 ◽  
Vol 154 (2) ◽  
pp. 287-297 ◽  
Author(s):  
Kimberly Blackwell ◽  
Howard Burris ◽  
Patricia Gomez ◽  
N. Lynn Henry ◽  
Steven Isakoff ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Aromatase Inhibitor ◽  
Dose Escalation ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Dose Escalation Study ◽  
Pi3k Inhibitors ◽  
Hormone Receptor Positive

Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR+) metastatic breast cancer (MBC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 531-531
Author(s):  
Antoinette R. Tan ◽  
Serena Tsan-Lai Wong ◽  
Robert D. Warren ◽  
Jennifer Eng-Wong ◽  
Minetta C. Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
First Line ◽  
First Line Therapy ◽  
Hormone Receptor Positive ◽  
Line Therapy

scholarly journals A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer

2015 ◽  
Vol 112 (5) ◽  
pp. 819-824 ◽  
Author(s):  
T Sakiyama ◽  
J Tsurutani ◽  
T Iwasa ◽  
H Kawakami ◽  
Y Nonagase ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Phase I ◽  
Dose Escalation ◽  
Metastatic Breast ◽  
Dose Escalation Study
Sign in / Sign up

Export Citation Format

Share Document